
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Kidney Function Tests Market**

According to Intelli, the U.S. Kidney Function Tests Market size was valued at USD 305.89 Million in 2024 and is projected to reach USD 485.86 Million by 2032, growing at a compound annual growth rate (CAGR) of 6.45%, during the forecast period of 2024 to 2032.



Kidney function tests are a critical group of clinical diagnostics used to evaluate how effectively the kidneys are performing their vital roles in the body. The kidneys are essential for filtering waste products, excess fluids, and electrolytes from the bloodstream, regulating blood pressure, maintaining acid-base balance, and stimulating red blood cell production. When kidney function is impaired, these processes are disrupted, potentially leading to serious health complications such as hypertension, anemia, electrolyte imbalances, or even kidney failure. Early detection of kidney dysfunction is therefore essential, and this is where kidney function tests play a pivotal role. Kidney function tests comprise a series of blood and urine examinations that assess crucial indicators of renal performance. The most frequently used tests include serum creatinine, blood urea nitrogen (BUN), glomerular filtration rate (GFR), and urinalysis. Each test provides distinct and valuable information: serum creatinine indicates how well the kidneys are clearing waste from the bloodstream, GFR estimates the overall efficiency of kidney filtration; and urinalysis helps detect abnormalities like proteinuria, hematuria, or urinary casts, all of which may signal underlying kidney disease. These diagnostic tools are vital for identifying and tracking both acute and chronic kidney disorders. They are routinely administered to monitor kidney health in individuals with high-risk profiles, including those with diabetes, hypertension, cardiovascular disease, or a family history of renal conditions. Additionally, kidney function tests play a key role in guiding the safe administration of medications, particularly those that are primarily eliminated through renal pathways. By informing treatment decisions and enabling early intervention, these tests serve as essential components in the prevention and management of kidney-related illnesses.

In an era of rising chronic kidney disease (CKD) prevalence, fueled by lifestyle-related illnesses, the role of kidney function tests has become more prominent than ever.

**U.S. Kidney Function Tests Market Definition**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe U.S. Kidney Function Tests Market refers to the sector within the American healthcare and diagnostics industry that focuses on the development, production, distribution, and utilization of various diagnostic tests aimed at assessing kidney health and function. This market encompasses products and services provided by clinical laboratories, hospitals, diagnostic centers, point-of-care testing providers, and research institutions. It includes both reagent kits and analyzers used in conducting these tests, as well as software solutions integrated into automated systems for enhanced accuracy and efficiency. Fundamentally, the U.S. Kidney Function Tests Market serves as a critical segment within the larger in-vitro diagnostics (IVD) and nephrology ecosystem. It plays an essential role in the early detection, ongoing monitoring, and clinical management of kidney-related conditions, directly impacting the health outcomes of millions of individuals at risk for or affected by renal disorders.

**U.S. Kidney Function Tests Market Overview**

The growth of the U.S. Kidney Function Tests Market is propelled by a combination of demographic, clinical, technological, and policy-related drivers. One of the most significant factors is the rising prevalence of CKD, largely fueled by increasing rates of diabetes and hypertension, the two leading causes of renal impairment. The aging population is another major driver. As kidney function naturally declines with age, the growing number of elderly individuals, who are more susceptible to renal disorders, has heightened the need for regular kidney health monitoring. Advancements in diagnostic technologies and automation are significantly transforming the landscape of kidney function testing. Cutting-edge developments in point-of-care testing, automated analyzers, and biomarker identification have greatly enhanced the precision, efficiency, and accessibility of renal diagnostics. These innovations allow for quicker turnaround times and more accurate results, supporting timely clinical decisions and improved patient care. Notably, the widespread adoption of estimated glomerular filtration rate (eGFR) calculations and microalbuminuria testing has become a standard component in routine screenings, enabling the early identification and management of kidney disease at its onset. The expanding emphasis on preventive healthcare and value-based care models has further boosted the adoption of kidney function tests. Insurance coverage improvements and government initiatives like Medicare's CKD management programs have made these tests more accessible and cost-effective, particularly for at-risk populations.

A close-up of hands holding a tablet and a pen

Description automatically generated

Additionally, the growing burden on healthcare systems due to late-stage kidney disease and the high costs of dialysis and transplant procedures have prompted a strategic shift toward early diagnosis and intervention, further strengthening the demand for reliable kidney function diagnostics.

**U.S. Kidney Function Tests Market Segmentation**

The U.S. Kidney Function Tests Market is segmented across several key dimensions to better understand the dynamics of demand, innovation, and distribution. These segments typically include test type, product type, and end user, each offering a unique view into market trends and growth opportunities.

**U.S. Kidney Function Tests Market, By Test Type**

* **Blood Tests**
* **Serum Creatinine**
* **Blood Urea Nitrogen (BUN)**
* **Estimated Glomerular Filtration Rate (eGFR)**
* **Cystatin C**
* **Urine Tests**
* **Urinalysis (Dipstick, Microscopic)**
* **Microalbuminuria Test**
* **24-Hour Urine Protein Test**
* **Creatinine Clearance Test**

The U.S. Kidney Function Tests Market, when segmented by test type, is predominantly led by blood tests. This dominance is largely attributed to the clinical reliability and routine use of serum creatinine, BUN, and eGFR in assessing kidney health. Additionally, the growing adoption of Cystatin C as a more sensitive biomarker for kidney function has further strengthened the segment's growth. Meanwhile, urine tests including urinalysis, microalbuminuria, and 24-hour urine protein tests, continue to hold a significant share, particularly in diabetes and hypertension monitoring, where early protein leakage can signal nephropathy.

A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Kidney Function Tests Market, By Product Type**

* **Reagents & Kits**
* **Instruments & Analyzers**
* **Software & Services**

The U.S. Kidney Function Tests Market, segmented by product type, sees reagents and kits leading the market with a substantial share, driven by the widespread use of diagnostic reagents in both clinical and point-of-care settings. Instruments and analyzers follow closely, accounting for a significant portion of the market as demand grows for automated clinical chemistry analyzers and high-throughput urine analyzers, which streamline testing processes and improve diagnostic accuracy. Software and services, while representing a smaller segment, are rapidly gaining traction due to their ability to enhance data integration, patient monitoring, and personalized treatment plans.

**U.S. Kidney Function Tests Market, By End User**

* **Hospitals**
* **Diagnostic Laboratories**
* **Ambulatory Surgical Centers (ASCs)**
* **Home Care Settings**

In the U.S. Kidney Function Tests Market, hospitals dominate the end-user segment, holding the largest share due to their advanced infrastructure, high patient volume, and comprehensive diagnostic services. Diagnostic laboratories follow closely, benefiting from their specialized focus on high-throughput testing and the ability to conduct detailed kidney function assessments for patients across multiple healthcare settings. Ambulatory Surgical Centers (ASCs) have also seen an increase in demand for kidney function testing, particularly in pre-operative evaluations and outpatient care, where efficiency and quick results are paramount. Home care settings are emerging as a growing end user, driven by the rise of point-of-care testing solutions and increasing patient preference for at-home health monitoring, particularly for chronic kidney disease patients who require regular monitoring.

A close-up of hands holding a tablet and a pen

Description automatically generated**Key Players**

The “U.S. Kidney Function Tests Market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, Thermo Fisher Scientific, Danaher Corporation, Beckman Coulter, Sysmex Corporation, Randox Laboratories, Nova Biomedical, Bio-Rad Laboratories, Arkray USA, Merck Group, Quest Diagnostics, LabCorp, Philips Healthcare, Fujifilm Medical Systems, PerkinElmer, NephroCheck among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2025, INNOVATE Corp. recently received FDA approval for its MediBeacon ® TGFR device, marking a significant advancement in kidney function assessment technology. It is a groundbreaking diagnostic tool, designed to provide real-time, accurate measurement of GFR, a critical indicator of kidney function.
* In 2025, Vanrafia (atrasentan), a selective endothelin A receptor antagonist, was approved by the FDA. This approval provides a new treatment option for individuals with this kidney condition, helping to manage protein levels in the urine and potentially slowing disease progression.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Kidney Function Tests Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be A close-up of hands holding a tablet and a pen

Description automatically generatedused to assess the competitive landscape U.S. Kidney Function Tests Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. KIDNEY FUNCTION TESTS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. KIDNEY FUNCTION TESTS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. KIDNEY FUNCTION TESTS MARKET, BY TEST TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Blood Tests

5.2.1 Serum Creatinine

5.2.2 Blood Urea Nitrogen (BUN)

5.2.3 Estimated Glomerular Filtration Rate (eGFR)

5.2.4 Cystatin C

5.3 Urine Tests

5.3.1 Urinalysis (Dipstick, Microscopic)

5.3.2 Microalbuminuria Test

5.3.3 24-Hour Urine Protein Test

5.3.4 Creatinine Clearance Test

**6 U.S. KIDNEY FUNCTION TESTS MARKET, BY PRODUCT TYPE**

6.1 Overview

6.2 Reagents & Kits

6.3 Instruments & Analyzers

6.4 Software & Services

**7** **U.S. KIDNEY FUNCTION TESTS MARKET, BY END USER**

7.1 Overview

7.2 Hospitals

7.3 Diagnostic Laboratories

A close-up of hands holding a tablet and a pen

Description automatically generated 7.4 Ambulatory Surgical Centers (ASCs)

7.5 Home Care Settings

1. **U.S. KIDNEY FUNCTION TESTS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

**9.1 Abbott Laboratories**

* + 1. Overview
    2. Financial Performance
    3. Product Outlook
    4. Key developments
  1. **Siemens Healthineers**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Roche Diagnostics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Thermo Fisher Scientific**
     1. A close-up of hands holding a tablet and a pen

        Description automatically generatedOverview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Danaher Corporation**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Beckman Coulter**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Sysmex Corporation**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Randox Laboratories**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Nova Biomedical**
     1. A close-up of hands holding a tablet and a pen

        Description automatically generatedOverview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Bio-Rad Laboratories**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Arkray USA**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Merck Group**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Quest Diagnostics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **LabCorp**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  7. **Philips Healthcare**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **Fujifilm Medical Systems**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  9. **PerkinElmer**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  10. **NephroCheck**
      1. Overview
      2. Financial Performance
      3. Product Outlook
      4. Key developments

1. **KEY DEVELOPMENTS**
   1. A close-up of hands holding a tablet and a pen

      Description automatically generated Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research